Ongoing phase III trials are now evaluating odronextamab in earlier lines of therapy: OLYMPIA-3 is comparing odronextamab-CHOP to R-CHOP in newly diagnosed DLBCL [38], while OLYMPIA-4 is assessing odronextamab vs. standard-of-care regimens in R/R aggressive B-cell lymphoma [39]. This evidence concerns the gene DDIT3 and B-cell non-Hodgkin lymphoma.